Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

JAK Inhibitors, Oral Minoxidil Reshape Hair Loss Care

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

What Are Some Tips for Off-Label Medication Use in Dermatology?

Natasha Mesinkovska, MD, PhD, speaks on the potential impact that an additional approved therapy like upadacitinib could have on younger patients with alopecia areata.

What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata

This interview on a possible upcoming therapeutic option for severe alopecia areata highlights information regarding upadacitinib (Rinvoq) and its potential.

How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD

In this Q&A interview, Hordinsky was asked about recent 1-year data on clascoterone solution 5% in androgenetic alopecia (AGA).

Q&A: 1-Year Efficacy Data on Clascoterone 5% in Androgenetic Alopecia, With Maria Hordinsky, MD

AbbVie submitted an sNDA to the FDA seeking approval of upadacitinib for severe alopecia areata in adults and adolescents.

Upadacitinib sNDA Submitted to FDA for Severe Alopecia Areata

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 04/19

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Check out exclusive expert interviews of late breaking data from AAD 2026.